Search
Nefiracetam
go.drugbank.com/drugs/DB13082InvestigationalNefiracetam has been used in trials studying the treatment of Alzheimer's Disease.
Categories: Compounds used in a research, industrial, or household settingCMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
TGAAC09
go.drugbank.com/drugs/DB06363InvestigationaltgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins. … It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection.
Ocrylate
go.drugbank.com/drugs/DB15086ExperimentalOcrylate is under investigation in clinical trial NCT01918059 (Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive).
Categories: Compounds used in a research, industrial, or household settingLevoglucose
go.drugbank.com/drugs/DB12970InvestigationalLevoglucose has been used in trials studying the diagnostic of Bowel Cleansing Prior to Colonoscopy.
Categories: Compounds used in a research, industrial, or household settingChlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin I-131 is investigated in clinical trials for treating brain cancer. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.
Categories: Complex MixturesDengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Dengue virus serotype 3
go.drugbank.com/drugs/DB22666Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
TRX1
go.drugbank.com/drugs/DB05863ExperimentalTRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
ATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.